Reimbursement is always a hot topic in urologic care, especially with regards to specific procedures. While individual payors may vary with regards to what they pay for specific evaluation and management (E&M) and procedures (CPT codes), almost all reimbursement is ultimately driven by what rates Medicare will pay and/or how many Relative Value Units (RVU’s) Medicare will assign to a specific E&M or CPT code. This post will review reimbursement trends for urodynamics in 2020 (UDS).
I am entrepreneur, so I see the business world primarily through an entrepreneur’s eyes. My role as CEO of BHN takes me inside many large hospitals and clinics. I am always amazed at how capital intensive these operations are. They have a device or machine for everything, and all the people with the right skills to operate the equipment as well. As an entrepreneur, this just does not make sense to me. As entrepreneur I've learned to look at capital as a very precious resource. For hospitals, it certainly makes sense to have certain devices/equipment present for critical care needs (i.e. a defibrillator), but for other assets it does not make sense. It would seem more logical and cost effective to share some of these capital-intensive resources with other locations or even other hospitals.
I have the benefit (and sometimes curse) of having an engineering degree and a finance degree. Due to this background I tend to analyze everything. In dealing with clinics and hospitals of all sizes, I see numerous purchase decisions being made. Sometimes the purchase decision is related to direct purchase of medical equipment, and sometimes it's related to a rent rather than buy decision.